Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
Loading...
Download
Official URL
Full text at PDC
Publication date
2021
Authors
Sáenz Francés, Federico
Morales Fernández, Laura
Perucho González, Lucía
Fernández Vidal, Ana M.
García Sáenz, Sofía
Sánchez Jean, Rubén
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature publishing group
Citations
Exportar
Citation
Martínez De La Casa Fernández-Borrella, J. M., Sáenz Francés, F., Morales Fernández, L. et al. «Clinical Outcomes of Combined Preserflo Microshunt Implantation and Cataract Surgery in Open-Angle Glaucoma Patients». Scientific Reports, vol. 11, n.o 1, agosto de 2021, p. 15600. DOI.org (Crossref), https://doi.org/10.1038/s41598-021-95217-x.
Abstract
To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients.